NO20016115D0 - Substituerte heterocykelkondenserte gamma-karboliner - Google Patents

Substituerte heterocykelkondenserte gamma-karboliner

Info

Publication number
NO20016115D0
NO20016115D0 NO20016115A NO20016115A NO20016115D0 NO 20016115 D0 NO20016115 D0 NO 20016115D0 NO 20016115 A NO20016115 A NO 20016115A NO 20016115 A NO20016115 A NO 20016115A NO 20016115 D0 NO20016115 D0 NO 20016115D0
Authority
NO
Norway
Prior art keywords
carbolines
substituted heterocycle
gamma
condensed
condensed gamma
Prior art date
Application number
NO20016115A
Other languages
English (en)
Other versions
NO20016115L (no
Inventor
Albert J Robichaud
Taekyu Lee
Wei Deng
Ian S Mitchell
Wenting Chen
Christopher D Mcclung
Emilie J B Calvello
David M Zawrotny
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20016115D0 publication Critical patent/NO20016115D0/no
Publication of NO20016115L publication Critical patent/NO20016115L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20016115A 1999-06-15 2001-12-14 Substituerte heterosykelkondenserte gamma-karbolin NO20016115L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13932199P 1999-06-15 1999-06-15
PCT/US2000/016375 WO2000077001A1 (en) 1999-06-15 2000-06-15 Substituted heterocycle fused gamma-carbolines

Publications (2)

Publication Number Publication Date
NO20016115D0 true NO20016115D0 (no) 2001-12-14
NO20016115L NO20016115L (no) 2002-02-12

Family

ID=22486095

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20016128A NO20016128L (no) 1999-06-15 2001-12-14 Substituerte, heterocykliske, fuserte <gamma>-karboliner
NO20016116A NO20016116L (no) 1999-06-15 2001-12-14 Substituerte heterocykelfuserte <gamma>-karboliner
NO20016115A NO20016115L (no) 1999-06-15 2001-12-14 Substituerte heterosykelkondenserte gamma-karbolin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20016128A NO20016128L (no) 1999-06-15 2001-12-14 Substituerte, heterocykliske, fuserte <gamma>-karboliner
NO20016116A NO20016116L (no) 1999-06-15 2001-12-14 Substituerte heterocykelfuserte <gamma>-karboliner

Country Status (19)

Country Link
US (7) US6552017B1 (no)
EP (3) EP1189904B1 (no)
JP (3) JP4863591B2 (no)
CN (3) CN1370176A (no)
AR (3) AR024379A1 (no)
AT (3) ATE277048T1 (no)
AU (3) AU5737900A (no)
BR (3) BR0012086A (no)
CA (3) CA2381322A1 (no)
DE (3) DE60014079T2 (no)
ES (3) ES2228549T3 (no)
HK (3) HK1042480A1 (no)
IL (3) IL145998A0 (no)
MX (3) MXPA01012914A (no)
NO (3) NO20016128L (no)
NZ (1) NZ516031A (no)
TR (1) TR200103658T2 (no)
WO (3) WO2000077001A1 (no)
ZA (1) ZA200109735B (no)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
WO2000077001A1 (en) * 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
JP2004509894A (ja) 2000-09-20 2004-04-02 ファルマシア・アンド・アップジョン・カンパニー 置換アゼピノ［４，５−ｂ］インドリン誘導体
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
RU2003121304A (ru) * 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
AU2002259312B2 (en) * 2001-06-01 2007-01-04 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
CA2447156A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
ATE318821T1 (de) * 2001-06-01 2006-03-15 Alcon Inc Pyranoindazole und ihre verwendung in der glaukombehandlung
US6720316B2 (en) 2001-08-06 2004-04-13 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
BR0212676A (pt) 2001-09-21 2006-05-23 Upjohn Co compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos
EP1436294A1 (en) * 2001-10-18 2004-07-14 PHARMACIA &amp; UPJOHN COMPANY Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
JP2006501245A (ja) * 2002-08-30 2006-01-12 アルコン，インコーポレイテッド 置換された５−クロマン−５−イル−エチルアミン化合物および緑内障の治療のためのその使用
BR0316775A (pt) 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
CN1968932A (zh) 2004-06-18 2007-05-23 惠氏公司 制备6－烷基－5－芳基磺酰基－二氢菲啶的方法
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP1981337B1 (en) * 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) * 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
AU2015218433B2 (en) * 2008-05-27 2017-07-27 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
TW201018694A (en) * 2008-09-29 2010-05-16 Abbott Lab Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011044134A1 (en) 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9193728B2 (en) * 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US8993572B2 (en) * 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2981266B1 (en) * 2013-03-04 2018-01-03 Daya CNS LLC Pentacyclic pyridoindolobenz[b,d]azepine derivatives and uses thereof
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10646648B2 (en) 2015-04-01 2020-05-12 Becton, Dickinson And Company IV flow management systems and methods
EP3286172B1 (en) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
LT3532459T (lt) 2016-10-26 2023-11-10 Constellation Pharmaceuticals, Inc. Lsd1 inhibitoriai ir jų medicininis panaudojimas
WO2018106916A1 (en) * 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
WO2018126140A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) * 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
RS67906B1 (sr) 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
EP3811371A1 (en) 2018-06-21 2021-04-28 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
CN109100437A (zh) * 2018-07-22 2018-12-28 邯郸学院 仲胺类抗抑郁药物的质谱检测方法
WO2020023782A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020051317A1 (en) 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
KR20210104785A (ko) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
JP7377871B2 (ja) * 2018-12-21 2023-11-10 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) * 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
IL286938B1 (en) * 2019-04-04 2026-05-01 Intra Cellular Therapies Inc Methods for treating neuropathic pain
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
MX2022004983A (es) 2019-11-01 2022-09-23 Aquestive Therapeutics Inc Composiciones de profarmaco y metodos de tratamiento.
CA3159389A1 (en) 2019-11-14 2021-05-20 Aquestive Therapeutics, Inc. Multimodal compositions comprising diazepam and methods of treatment
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
LT4076461T (lt) 2019-12-19 2026-06-25 Intra-Cellular Therapies, Inc. Lumateperonas, skirtas panaudoti šizofrenijos gydymui
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
US20230339949A1 (en) * 2020-10-09 2023-10-26 Shujing Biopharma Co., Ltd HETEROCYCLIC SUBSTITUTED FUSED y-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF
CN112062767B (zh) * 2020-10-20 2022-03-11 杭州科巢生物科技有限公司 一种卢美哌隆的制备方法及其中间体
JP2024505429A (ja) 2021-01-15 2024-02-06 アクエスティブ セラピューティクス インコーポレイテッド プロドラッグ組成物及び治療の方法
US20220347117A1 (en) 2021-03-09 2022-11-03 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
US20250136601A1 (en) * 2022-01-14 2025-05-01 Shanghaitech University Cyclopiperidine compound, preparation method therefor, and use thereof
CN114456149A (zh) * 2022-02-24 2022-05-10 中国科学技术大学 一种多巴胺drd2受体拮抗剂及其用途
JP2025509569A (ja) * 2022-03-14 2025-04-11 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20250320214A1 (en) * 2022-03-14 2025-10-16 Intra-Cellular Therapies, Inc. Organic compounds
US20250195510A1 (en) 2022-05-18 2025-06-19 Intra-Cellular Therapies, Inc. Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
KR20250123225A (ko) 2022-12-30 2025-08-14 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN121152625A (zh) 2023-02-17 2025-12-16 细胞内治疗公司 用于调节神经系统的卢美哌隆和其衍生物
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
CN119930620A (zh) * 2024-02-05 2025-05-06 和径医药科技（上海）有限公司 四并环类化合物、其制备方法、药物组合物及应用
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299078A (en) * 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3892746A (en) * 1969-06-09 1975-07-01 American Home Prod Pyrrolo{8 1,2,3-de{9 quinoxalin-2(3H)-ones and related compounds
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3891643A (en) * 1972-05-15 1975-06-24 American Home Prod Pyrrolo{8 1,2,3-de{9 quinoxalin-2-(3H)-ones and related compounds
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
JPS4949999A (no) * 1973-06-19 1974-05-15
FR2213283A1 (en) * 1973-11-15 1974-08-02 Inst Im Ordzhonikidze Pyrazino(1,2,3-ab)beta carbolines and homologues - antidepressants not acting by MAO inhibition
JPS569510B2 (no) * 1973-11-17 1981-03-02
US4088647A (en) 1976-02-04 1978-05-09 Glushkov Robert Georgievich Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same
US4219550A (en) * 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
EP0300541B1 (en) * 1987-07-20 1996-03-27 Duphar International Research B.V 8,9-anellated-1,2,3,4-tetrahydro-beta-carboline derivatives
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
EP0347980A1 (en) * 1988-06-20 1989-12-27 Duphar International Research B.V 8,9-Annelated beta-carbolines and 8,9-anelated-3,4-dihydro-beta-carbolines
EP0357417A1 (en) 1988-09-01 1990-03-07 Glaxo Group Limited Lactam derivatives
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
CA2011107A1 (en) 1990-02-28 1991-08-31 David E. Bays Lactam derivatives
US5512575A (en) 1991-08-15 1996-04-30 Zeneca Limited Methanoanthraceneyl methyl piperidinyl compounds
CA2174543A1 (en) 1993-10-20 1995-04-27 Nobuyuki Yasuda Indole derivative
US5654139A (en) 1994-09-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Allelic variation of the serotonin 5HT2c receptor
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US6107324A (en) 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6140509A (en) 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
PE20010052A1 (es) * 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
WO2000077001A1 (en) * 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines

Also Published As

Publication number Publication date
ES2223537T3 (es) 2005-03-01
MXPA01012914A (es) 2004-04-21
IL145998A0 (en) 2002-07-25
US20040209864A1 (en) 2004-10-21
CN1370176A (zh) 2002-09-18
US7081455B2 (en) 2006-07-25
WO2000077010A3 (en) 2001-06-28
US6548493B1 (en) 2003-04-15
HK1042480A1 (zh) 2002-08-16
DE60014370D1 (de) 2004-11-04
EP1189904B1 (en) 2004-09-22
USRE39680E1 (en) 2007-06-05
ATE277048T1 (de) 2004-10-15
ATE277055T1 (de) 2004-10-15
IL147109A0 (en) 2002-08-14
NO20016128D0 (no) 2001-12-14
CN1370169A (zh) 2002-09-18
TR200103658T2 (tr) 2002-06-21
JP2003502336A (ja) 2003-01-21
AU5738000A (en) 2001-01-02
CN1371374A (zh) 2002-09-25
EP1189905B1 (en) 2004-09-29
NO20016128L (no) 2002-02-11
BR0012411A (pt) 2002-04-16
US7238690B2 (en) 2007-07-03
CA2374239A1 (en) 2000-12-21
JP4916633B2 (ja) 2012-04-18
DE60014083D1 (de) 2004-10-28
MXPA01012970A (es) 2003-10-14
HK1042481A1 (zh) 2002-08-16
AR024378A1 (es) 2002-10-02
JP2003502330A (ja) 2003-01-21
ATE277928T1 (de) 2004-10-15
EP1192165A2 (en) 2002-04-03
WO2000077001A1 (en) 2000-12-21
JP2003502331A (ja) 2003-01-21
DE60014370T2 (de) 2006-02-09
DE60014079D1 (de) 2004-10-28
CA2381322A1 (en) 2000-12-21
NZ516031A (en) 2003-10-31
CA2373920A1 (en) 2000-12-21
AR024377A1 (es) 2002-10-02
EP1189904A1 (en) 2002-03-27
US20040127482A1 (en) 2004-07-01
MXPA01012969A (es) 2003-10-14
BR0012084A (pt) 2002-04-02
US20060178362A1 (en) 2006-08-10
US6552017B1 (en) 2003-04-22
IL147108A0 (en) 2002-08-14
AU5737900A (en) 2001-01-02
NO20016116D0 (no) 2001-12-14
US20040034015A1 (en) 2004-02-19
JP4863591B2 (ja) 2012-01-25
AR024379A1 (es) 2002-10-02
NO20016116L (no) 2002-02-11
BR0012086A (pt) 2002-04-02
DE60014083T2 (de) 2006-03-02
ZA200109735B (en) 2004-01-27
ES2228549T3 (es) 2005-04-16
DE60014079T2 (de) 2006-03-02
AU5615900A (en) 2001-01-02
HK1043112A1 (zh) 2002-09-06
EP1192165B1 (en) 2004-09-22
JP4762465B2 (ja) 2011-08-31
WO2000077002A1 (en) 2000-12-21
EP1189905A1 (en) 2002-03-27
WO2000077010A2 (en) 2000-12-21
NO20016115L (no) 2002-02-12
ES2223536T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
NO20016115L (no) Substituerte heterosykelkondenserte gamma-karbolin
PT1224180E (pt) Azois substituidos
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE50007953D1 (de) Beleuchtungsanordung
DE50008613D1 (de) Sicherungsring
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50006013D1 (de) Anschlagpuffer
DE50003660D1 (de) Diacylhydrazinderivate
NO20022927D0 (no) Substituerte pyrrazoler
DE50003259D1 (de) Textilie
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50006759D1 (de) Piperidinalkohole
DE50009208D1 (de) Hydroxyphenylvinylthiazole
ATE440824T1 (de) Nitro-sulfobenzamide
DE10082008D2 (de) Ausbeulgerät
DE50006829D1 (de) Benzoylpyridazine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application